Broad-spectrum neutralizing monoclonal antibodies against group A rotavirus and their applications

By designing monoclonal antibodies against group A rotavirus with specific amino acid sequences, the problem of insufficient neutralizing ability against multiple rotavirus genotypes in existing technologies has been solved, achieving broad-spectrum neutralization and diagnostic effects, and is suitable for the inhibition and detection of rotavirus.

CN123106887APending Publication Date: 2026-11-17JILIN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611586147.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-14
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies make it difficult to develop neutralizing monoclonal antibodies with high affinity and broad spectrum that bind to multiple rotaviruses, especially different genotypes of porcine group A rotavirus, resulting in limited therapeutic and diagnostic efficacy.

Method used

A monoclonal antibody against group A rotavirus was designed, containing a CDR region composed of a specific amino acid sequence, which binds to human or non-human mammalian framework regions and is prepared into antigen-binding fragments such as Fab, Fab′, F(ab′)2, and Fv. It is applied to recombinant vectors and host cell expression to prepare antibodies for the inhibition, detection, and diagnosis of rotavirus.

Benefits of technology

It achieves broad-spectrum neutralization of multiple group A rotavirus genotypes, effectively inhibiting viral infection and providing an efficient diagnostic and detection method suitable for clinical diagnosis and disease control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106887A_ABST
    Figure CN123106887A_ABST
Patent Text Reader

Abstract

This invention discloses a broad-spectrum neutralizing monoclonal antibody against group A rotavirus and its applications, belonging to the field of immunoglobulins. Specifically, it discloses a monoclonal antibody against group A rotavirus or its antigen-binding fragment, which contains VHCDR1, VHCDR2, and VHCDR3 with amino acid sequences of GYALTAYW, INPNDYA, and ARSAVDYW, respectively; and VLCDR1, VLCDR2, and VLCDR3 with amino acid sequences of QSLLNSAGKTY, EVS, and WQGTHFPWT, respectively. The monoclonal antibody of this invention can recognize six genotypes (P[1], P[6], P[7], P[8], P[13], and P[23]) of group A rotavirus and has good neutralizing ability. It can be used for serological diagnosis and evaluation of immunization effects of rotavirus, and has broad application prospects in clinical diagnosis and other fields.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of immunoglobulins, specifically relating to a broad-spectrum neutralizing monoclonal antibody against group A rotavirus and its applications. Background Technology

[0002] Rotavirus (RV) is a significant zoonotic pathogen that can infect multiple hosts. It primarily affects young animals, causing gastroenteritis with clinical symptoms including diarrhea, vomiting, and dehydration, which can lead to death in severe cases. Porcine rotavirus (PoRV) is a major cause of diarrhea in newborn piglets, widely prevalent globally and causing substantial economic losses. Porcine rotavirus A (PoRVA) has the highest detection rate and has become the second most important diarrheal pathogen after porcine epidemic diarrhea virus (PEDV). PoRVA strains exhibit high genetic diversity, with the main prevalent genotypes including G2-G5, G9, G11 and P[1], P[6], P[7], P

[23] , P

[13] , and P

[23] . Among them, G5P

[13] and G9P

[23] have gradually replaced G5P[7] and become the dominant genotype combinations, accounting for 49.6% of all detected genotype combinations.

[0003] Due to the increasing prevalence of PoRVA and the large number of genotypes of the virus, with significant genetic and antigenic differences between different genotypes, in-depth research and development of broad-spectrum neutralizing monoclonal antibodies with high affinity, the ability to specifically bind to more rotaviruses, and neutralizing effects have broad clinical application value for the treatment and diagnosis of rotavirus-related diseases, as well as the prevention and control of rotavirus. Summary of the Invention

[0004] One of the objectives of this invention is to provide a broad-spectrum neutralizing monoclonal antibody against group A rotavirus and its applications.

[0005] To achieve the above objectives, the present invention first provides a monoclonal antibody against group A rotavirus or its antigen-binding fragment thereof, wherein the monoclonal antibody or its antigen-binding fragment comprises VHCDR1 with the amino acid sequence GYALTAYW (SEQ ID No. 18), VHCDR2 with the amino acid sequence INPNDYA (SEQ ID No. 19), VHCDR3 with the amino acid sequence ARSAVDYW (SEQ ID No. 20); and VLCDR1 with the amino acid sequence QSLLNSAGKTY (SEQ ID No. 21), VLCDR2 with the amino acid sequence EVS, and VLCDR3 with the amino acid sequence WQGTHFPWT (SEQ ID No. 22).

[0006] VHCDR1, VHCDR2, and VHCDR3 represent CDR1, CDR2, and CDR3 of the heavy chain variable region (VH), respectively; VLCDR1, VLCDR2, and VLCDR3 represent CDR1, CDR2, and CDR3 of the light chain variable region (VL), respectively.

[0007] The sequence of the CDR (Complementary Decision Region) is defined according to the IMGT numbering system.

[0008] The antigen-binding fragment may include, but is not limited to, Fab, Fab′, F(ab′)2, antibody variable region (Fv), disulfide bond-stabilized Fv (dsFv), single-domain antibody (SdAb), single-chain antibody (ScFv), minibody, and minimum recognition unit (MRU).

[0009] Both the heavy chain and light chain variable regions contain a framework region (FR, the region outside the CDR within the variable region). The framework region can be derived from humans or non-human mammals (such as mice, rats, guinea pigs, sheep, rabbits, horses, monkeys, camels, alpacas, etc.). The framework region typically does not contact the antigen or has very little contact with it, and it can provide structural support for the CDR. Part or all of the framework region of the monoclonal antibody or its antigen-binding fragment described in this invention can be replaced with any suitable framework region, such as a human framework region, a monkey framework region, etc.

[0010] Furthermore, the monoclonal antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of the heavy chain variable region may be as shown in SEQ ID No. 1, and the amino acid sequence of the light chain variable region may be as shown in SEQ ID No. 3.

[0011] Furthermore, the monoclonal antibody or its antigen-binding fragment may further include a heavy chain constant region (CH) and a light chain constant region (CL). The heavy chain constant region may be selected from the heavy chain constant regions of IgG, IgA, IgM, IgD, and IgE. The heavy chain constant region may also be selected from the CH1, Fc, and CH3 domains. The light chain constant region may be selected from Kappa (κ) and lambda (λ) type light chain constant regions. The heavy chain constant region and light chain constant region may be derived from humans or non-human mammals (such as mice, rats, guinea pigs, rabbits, sheep, camels, etc.).

[0012] Furthermore, the heavy chain constant region can be selected from the heavy chain constant regions of human IgG subclasses such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant region can also be selected from the heavy chain constant regions of mouse IgG subclasses such as IgG1, IgG2a, IgG2b, IgG2c, IgG3, IgG4, IgG5, and IgG6.

[0013] Furthermore, the heavy chain constant region may be the mouse IgG2a heavy chain constant region; the light chain constant region may be the mouse Kappa (κ) type light chain constant region.

[0014] In some embodiments, the nucleotide sequence of the heavy chain constant region may be SEQ ID No. 5; the amino acid sequence of the heavy chain constant region may be SEQ ID No. 6; the nucleotide sequence of the light chain constant region may be SEQ ID No. 7; and the amino acid sequence of the light chain constant region may be SEQ ID No. 8.

[0015] The present invention also provides a biomaterial, which may be any of the following: A1) Nucleic acid molecules that encode the heavy chain variable region and light chain variable region of the monoclonal antibody or its antigen-binding fragment described herein; A2) An expression cassette containing the nucleic acid molecule described in A1); A3) A recombinant vector containing the nucleic acid molecules described in A1); A4) Recombinant microorganisms containing the nucleic acid molecules described in A1); A5) Recombinant host cells containing the nucleic acid molecules described in A1).

[0016] Furthermore, all of the biological materials described herein can express the monoclonal antibody or its antigen-binding fragment.

[0017] In the above-mentioned biological materials, the recombinant vector can be a recombinant cloning vector or a recombinant expression vector.

[0018] The recombinant vector can be constructed using a cloning vector. The construction of cloning vectors is typically for purposes such as large-scale amplification of the target gene, restriction enzyme digestion, sequencing, and facilitating long-term preservation and immediate use of the target gene. Common cloning vectors include the pGEM series, pUC series, pMD18-T, pBluescript, and pBR322. Those skilled in the art can select a suitable cloning vector as needed.

[0019] The recombinant vector can be constructed using expression vectors (such as prokaryotic and eukaryotic expression vectors). The structure of expression vectors is well known to those skilled in the art. Expression vectors typically contain elements required for target gene expression, such as promoters, multiple cloning sites, terminators, and ribosome binding sites, and may also contain selection marker genes (such as the kanamycin resistance gene kanr, the neomycin resistance gene neo, and the chloramphenicol resistance gene cat). Expression vectors can be constructed using any method known in the art (such as recombination techniques, synthetic techniques, etc.) or can be commercially available. Those skilled in the art can choose a suitable expression vector as needed.

[0020] Among them: prokaryotic expression vectors can be selected from Escherichia coli expression vectors (such as pET series vectors, pGEX series vectors, pMAL series vectors), Bacillus subtilis expression vectors (such as pHT01, pHT43, pWB980) and Streptomyces expression vectors (such as pIJ702, pHJL197, pSET152). Eukaryotic expression vectors can be selected from: (1) yeast expression vectors (such as pYES2, pPICZaA, pUG6). (2) insect cell expression vectors (such as pMT-Bip-V5-HisA, pAc5.1 and other plasmid vectors, as well as baculovirus expression vectors); wherein, the baculovirus expression vectors can be selected from Bac-to-Bac expression systems (including baculovirus expression vectors such as pFastBac1) and MultiBac expression systems (including baculovirus expression vectors such as pFBDM). (3) Mammalian cell expression vectors (such as plasmid vectors like pCMV3, pEGFP, pcDNA3.1, pcDNA3.4, etc., and animal virus expression vectors). The animal virus expression vectors may be selected from lentiviral (LV) vectors, retroviral vectors, adeno-associated virus (AAV) vectors, adenovirus vectors, herpes simplex virus (HSV) vectors, poxvirus vectors, baculovirus vectors, papillomavirus vectors, Sendai virus vectors, and simian virus expression vectors.

[0021] Further, the recombinant vector described in A3) can be a recombinant expression vector obtained by cloning the coding gene of the monoclonal antibody or its antigen-binding fragment described in this invention into an expression vector. Although the expression vector used in the embodiments provided in this invention is the pcDNA3.4 vector, this invention is not limited to this specific vector. Those skilled in the art can use other suitable expression vectors, as long as the expression vector can express the monoclonal antibody or its antigen-binding fragment described in this invention.

[0022] The microorganisms described herein may include bacteria, viruses, fungi, actinomycetes, algae, etc. Genes that can be used to clone or express the monoclonal antibodies or their antigen-binding fragments described in this invention include, such as *Escherichia coli*, *Corynebacterium glutamicum*, *Brevibacterium lactis*, *Pseudomonas*, *Bacillus subtilis*, *Agrobacterium tumefaciens*, yeasts (such as *Saccharomyces cerevisiae*, *Candida albicans*, *Methanolobacterium methylprednisolone*, *Pichia pastoris*), *Streptomyces*, as well as rotaviruses, baculoviruses, retroviruses (such as lentiviruses), adenoviruses, adeno-associated viruses, poxviruses, papillomaviruses, influenza viruses, papillomaviruses (such as SV40), and herpesviruses (such as herpes simplex virus), etc.

[0023] The host cell (also referred to as the recipient cell) mentioned herein can refer to any type of cell (including but not limited to plant cells and animal cells) used for vector introduction. Suitable host cells are those known in the art; for example, the animal cell can be a mammalian cell, including but not limited to Chinese hamster ovary cells (CHO cells), Chinese hamster ovary cell substrain (CHO-K1 cells), African green monkey kidney cells (Vero cells), SV40-transformed African green monkey kidney cells (COS cells), young hamster kidney cells (BHK cells), human HeLa cells, human embryonic kidney cells (HEK293 cells), etc.

[0024] In the above-mentioned biological materials, the nucleic acid molecule may be the DNA molecule shown in SEQ ID No. 2 and the DNA molecule shown in SEQ ID No. 4.

[0025] The DNA molecule shown in SEQ ID No. 2 encodes the amino acid sequence of the heavy chain variable region (VH) of the monoclonal antibody TAH028 in SEQ ID No. 1. The DNA molecule shown in SEQ ID No. 4 encodes the amino acid sequence of the light chain variable region (VL) of the monoclonal antibody TAH028 in SEQ ID No. 3.

[0026] The nucleic acid molecules described herein may also include nucleic acid molecules obtained by codon preference modification based on the nucleotide sequences shown in SEQ ID No. 2 and / or SEQ ID No. 4. Considering the degeneracy of codons and the codon preferences of different species, those skilled in the art may use codons suitable for expression in specific species as needed.

[0027] This invention also provides for the use of the monoclonal antibody or its antigen-binding fragment or biological material described herein in any of the following: B1) Use in the preparation of products for inhibiting or neutralizing rotavirus activity; B2) Application in the preparation of products for detecting rotavirus or rotavirus VP8* protein; B3) Application in the preparation of products for binding to rotavirus or rotavirus VP8* protein; B4) Use in the preparation of products for the diagnosis or auxiliary diagnosis of rotavirus infection or diseases caused by rotavirus infection; B5) Use in the preparation of products for screening or assisting in the screening of rotavirus infection or diseases caused by rotavirus infection.

[0028] Furthermore, the inhibition or neutralization of rotavirus activity described in B1) includes inhibiting or neutralizing rotavirus activity by binding to the rotavirus VP8* protein, thereby causing the rotavirus to lose its ability to bind to receptors and subsequently lose its ability to infect host cells.

[0029] Furthermore, the detection of rotavirus or rotavirus VP8* protein described in B2) includes the detection of any in vivo or in vitro VP8* protein based on the principle of antigen-antibody specific reaction. The detection of VP8* protein may be to detect whether the sample contains VP8* protein and / or to detect the amount of VP8* protein in the sample.

[0030] Further, the product described in B3) that binds to rotavirus or rotavirus VP8* protein can be a VP8* protein inhibitor, or a product used to isolate or purify VP8* protein, but is not limited thereto. Those skilled in the art know that, based on the principle of antigen-antibody specific reaction, products that specifically capture, enrich, and / or purify VP8* protein can be prepared by immobilizing the monoclonal antibody or its antigen-binding fragment described in this invention as an affinity ligand on a solid-phase support. For example, the monoclonal antibody or its antigen-binding fragment described in this invention can be prepared into an immunoaffinity chromatography column. Based on the principle that the antigen can be captured by the antibody when passing through the chromatography column, and that environmental conditions such as changing the pH value cause the antigen to dissociate from the column, VP8* protein can be screened and isolated.

[0031] Further, the diagnosis or auxiliary diagnosis of rotavirus infection or rotavirus-induced disease described in B4) may include the following steps: obtaining a sample from the subject, and then using the monoclonal antibody or its antigen-binding fragment described in this invention to detect the presence or content of rotavirus VP8* protein in the sample, and making a diagnosis or auxiliary diagnosis of rotavirus infection or rotavirus-induced disease based on the detection results.

[0032] Further, the screening or auxiliary screening for rotavirus infection or rotavirus-induced diseases described in B5) may include the following steps: obtaining a sample from the subject, and then using the monoclonal antibody or its antigen-binding fragment described in this invention to detect the presence or content of rotavirus VP8* protein in the sample, and screening for rotavirus infection or rotavirus-induced diseases based on the detection results.

[0033] The products described herein may include reagents, formulations, kits, chips, test strips, test cards, and immunosensors.

[0034] Furthermore, the subjects may be humans or non-human animals (such as pigs, cows, sheep, rabbits, cats, horses, deer, monkeys, chickens, dogs, etc.).

[0035] Furthermore, the rotavirus may be group A rotavirus (RVA).

[0036] Furthermore, the group A rotavirus (RVA) includes, but is not limited to, porcine group A rotavirus (PoRVA), bovine group A rotavirus (BRVA), and human group A rotavirus (HRVA).

[0037] Furthermore, the diseases caused by the rotavirus infection include, but are not limited to, rotavirus gastroenteritis and diarrhea.

[0038] In the above applications, the rotavirus may be group A rotavirus or group A rotavirus with the following genotypes: P[1], P[6], P[7], P[8], P

[13] and / or P

[23] .

[0039] The present invention also provides antibody conjugates comprising an antibody portion and a conjugation portion, wherein the antibody portion comprises a monoclonal antibody or an antigen-binding fragment thereof as described herein.

[0040] Furthermore, the antibody portion and the conjugated portion can be directly connected or covalently connected through a connector (such as a hydrazone bond, disulfide bond, thioether bond, or peptide bond).

[0041] Furthermore, the coupling portion may be a detectable marker.

[0042] Furthermore, the detectable markers include, but are not limited to, enzymes (such as horseradish peroxidase (HRP), alkaline phosphatase (AP), β-galactosidase, etc.), chemiluminescent reagents (such as acridine esters, acridine sulfonamides, luminol and its derivatives, ruthenium derivatives, etc.), and fluorescent dyes (such as FITC, DAPI, AMCA, CFSE, GFP, 7-AAD, Hoechst 33342, Pacific Blue, PE, PE-TR, PE-Cy7, PE-Cy5, PI, PerCP-Cy5.5, APC, APC-CY7, APC-H7, V500, Alexa). 700, BV480, BV510, BV605, BV785, BV711, BV421, etc.), near-infrared dyes (such as rhodamine, cyanine dyes, BODIPY dyes, squaric acid dyes, porphyrin dyes, etc.), radionuclides (such as 123I, 125I, 18F, 11C, 99mTc, etc.), biotin, magnetic resonance imaging nanoparticles, magnetic resonance imaging quantum dots, magnetic materials (such as magnetic beads, gadolinium-containing nanoparticles, superparamagnetic iron oxide nanoparticles), and colloidal gold.

[0043] Furthermore, the detectable marker may also include a tag protein. To facilitate the isolation, purification, detection, and / or localization of the monoclonal antibody or its antigen-binding fragment described herein, a tag protein may be attached to the amino or carboxyl terminus of the monoclonal antibody or its antigen-binding fragment. The tag protein may include, but is not limited to: His-tag, MBP (maltose-binding protein) tag protein, Flag tag protein, GST (glutathione thiotransferase) tag protein, Trx (thioredoxin) tag protein, nitrogen utilization substrate A (NusA) tag protein, SUMO tag protein, HA (influenza hemagglutinin) tag protein, Myc tag protein, LacZ tag protein, CBD (cellulose-binding domain) tag protein, phage T7 protein kinase (T7PK) tag protein, GFP (green fluorescent protein), CFP (cyan fluorescent protein), YFP (yellow-green fluorescent protein), mCherry (monomer red fluorescent protein), or AviTag tag protein. Those skilled in the art know how to select a suitable tag protein according to the desired purpose. The use of tags does not alter the function of the target protein; its purpose is to separate, purify, detect, or trace the protein. Therefore, the tag proteins applicable to the monoclonal antibodies or their antigen-binding fragments of this invention are not limited to specific types. Tag proteins can also be separated from the target protein by chemical cleavage methods or enzymatic methods known in the art (such as introducing protease cleavage sites and using TEV protease to remove the tag).

[0044] The present invention also provides a kit containing the monoclonal antibody or its antigen-binding fragment described herein, or the antibody-drug conjugate described herein.

[0045] Furthermore, the kit may have at least one of the following uses: 1) To diagnose or assist in the diagnosis of rotavirus infection or diseases caused by rotavirus infection; 2) Screening or assisting in the screening for rotavirus infection or diseases caused by rotavirus infection; 3) Detect rotavirus or rotavirus VP8* protein; 4) Bind to rotavirus or rotavirus VP8* protein (e.g., isolate or purify rotavirus VP8* protein).

[0046] The test samples for the kit can be environmental samples, blood samples (such as whole blood, plasma, serum), sputum samples, tissue samples, cell samples, fecal samples, etc., but are not limited to these.

[0047] Furthermore, the environmental samples may include, but are not limited to, food samples, environmental water samples, feed mill environmental samples (such as silos, conveyor belts, workbenches, ground, etc.), aquaculture environmental samples (such as sludge, aquaculture feed, soil, feed troughs, rags used for wiping the environment, swabs, aquaculture water, air, etc.), and surrounding environmental samples (such as transport vehicles, surrounding farmland, etc.).

[0048] Furthermore, the kit may be an enzyme-linked immunosorbent assay (ELISA) kit, a flow cytometry kit, an immunohistochemistry kit, an immunoblotting kit, an immunoprecipitation kit, an immunochromatographic kit, a chemiluminescent immunoassay kit, a colloidal gold immunoassay kit, or a fluorescent immunoassay kit, but is not limited thereto.

[0049] Furthermore, the kit may also include reagents required for immunoassay, such as labeled antibodies or antigens, magnetic microparticles, blocking solution, diluent, washing solution, chromogenic solution, and stop solution.

[0050] The various reagent components of the kit may be present in separate containers, or may be pre-assembled into a reagent mixture, either wholly or partially.

[0051] The components of the kit may be provided in solution form, such as an aqueous solution. When present in aqueous solution, the concentration or content of these components can be readily determined by those skilled in the art according to different needs. For example, for storage purposes, the components may be present at a higher concentration, which can be reduced to the working concentration by diluting the higher concentration solution when in operation or for use.

[0052] The kit may also contain, for example, buffers, preservatives, or protein stabilizers. The kit may also contain components necessary for detecting the detectable label, such as enzymes or substrates. The kit may also contain one or a series of control samples, which can be measured and compared to the test sample. The kit may have written instructions on or included with the kit container. The written instructions describe how to use the reagents included in the kit.

[0053] The present invention also provides a method for detecting rotavirus or rotavirus VP8* protein, the method comprising detecting rotavirus or rotavirus VP8* protein using the monoclonal antibody or its antigen-binding fragment, antibody conjugate or kit described herein.

[0054] Furthermore, the rotavirus may be a group A rotavirus.

[0055] The detection may include detecting the presence of VP8* protein in the sample, or the expression level or content of VP8* protein in the sample.

[0056] Furthermore, the method for detecting rotavirus or rotavirus VP8* protein may include contacting the monoclonal antibody or its antigen-binding fragment, the antibody conjugate or the kit described herein with the sample to be tested, and detecting the presence of rotavirus VP8* protein in the sample to be tested through an antigen-antibody reaction.

[0057] Furthermore, the method for detecting rotavirus or rotavirus VP8* protein may further include first labeling the monoclonal antibody or its antigen-binding fragment described herein with a detectable label; then contacting it with the sample to be tested, and detecting the presence of VP8* protein in the sample to be tested, or the content of VP8* protein in the sample to be tested, by detecting the detectable label.

[0058] The method for detecting VP8* protein can be an immunological assay, including but not limited to precipitation reaction, Western blotting, enzyme immunoassay (e.g., ELISA), double antibody sandwich ELISA, fluorescence-linked immunosorbent assay (FLISA), enzyme immunoassay (EIA), chemiluminescent immunoassay, fluorescence immunoassay, radioimmunoassay (RIA), colloidal gold immunochromatography (GIC), immunohistochemistry (IHC), colloidal gold immunochromatography (GICA), complement fixation reaction, multivariate immunoassay, and fluorescence immunochromatography.

[0059] The method for detecting VP8* protein can be for disease diagnosis, disease prognosis and / or disease treatment, or it can be for non-disease diagnosis, non-disease prognosis and non-disease treatment purposes.

[0060] The non-disease diagnosis, non-disease prognosis, and non-disease treatment purposes may be to detect whether rotavirus contamination exists in environmental samples (such as food samples, environmental water samples, etc.).

[0061] Furthermore, the method for detecting VP8* protein can be an ELISA detection method.

[0062] Furthermore, the method includes the step of coating a solid-phase support with the monoclonal antibody or its antigen-binding fragment or antibody-conjugate described herein to obtain an antibody-coated solid-phase support. The coating refers to binding onto the solid-phase support through physical adsorption.

[0063] Furthermore, the solid-phase carrier includes, but is not limited to, enzyme-labeled plates, membrane carriers (such as nitrocellulose membranes, glass cellulose membranes, or nylon membranes), microspheres, biochips, or magnetic beads.

[0064] The solid support material may include cellulose, croscarmellose, polystyrene, polyacrylamide, polyethylene, polypropylene, polyvinyl chloride, croscarmellose, glass, silicone rubber, or agarose gel.

[0065] The present invention also provides a method for preparing the monoclonal antibody or antigen-binding fragment thereof described herein, the method comprising expressing the monoclonal antibody or antigen-binding fragment thereof described herein in a host cell and recovering or separating the monoclonal antibody or antigen-binding fragment thereof.

[0066] Further, the preparation method may include the following steps: cloning the coding gene of the monoclonal antibody or its antigen-binding fragment described in this invention into an expression vector (such as a prokaryotic expression vector, a eukaryotic expression vector, or a viral expression vector) to obtain a recombinant expression vector; introducing the recombinant expression vector into a host cell to obtain a recombinant host cell expressing the monoclonal antibody or its antigen-binding fragment; culturing the recombinant host cell, and recovering or separating the monoclonal antibody or its antigen-binding fragment from the cultured recombinant host cell culture.

[0067] The coding gene can refer to any gene capable of encoding a protein (including antibodies). In the art, those skilled in the art, knowing the amino acid sequence of a protein, can obtain the nucleotide sequence of the coding gene of that protein according to the rules of the genetic codon. Due to the degeneracy of the codon, the nucleotide sequence encoding the same amino acid sequence is not unique.

[0068] Furthermore, the recovery or separation can be achieved by precipitation methods (such as salting out, organic solvent precipitation, octanoic acid-saturated ammonium sulfate precipitation, isoelectric point precipitation) or chromatographic techniques (such as ion exchange chromatography, affinity chromatography, gel filtration chromatography) from the culture (including all substances within the culture vessel).

[0069] Furthermore, the expression vector can be selected from prokaryotic expression vectors (such as Escherichia coli expression vectors (such as BL21 series expression cells, M15 expression cells, Top10 expression cells and Origamai series expression cells) and eukaryotic expression vectors (including yeast expression vectors (such as X33 cells, GS115 cells and SMD1168 cells), insect cell expression vectors (such as Sf21 cells, Sf-9 cells and Hi-5 cells), mammalian cell expression vectors (such as HET293 cells, CHO-K1 cells and CHO cells) etc.).

[0070] Furthermore, the method of introduction may include any of the following: (1) by chemical transformation (such as Ca 2+ (1) Induced transformation, polyethylene glycol-mediated transformation, or metal cation-mediated transformation, etc.) or physical transformation (such as electroporation transformation) to introduce the target gene or a recombinant vector containing the target gene into the host bacteria. (2) Transducing the target gene into the host bacteria through phage transduction. (3) Introducing the target gene into isolated animal cells (transfection) through calcium phosphate coprecipitation, cationic polymer methods (such as DEAE-dextran transfection), cationic liposome methods, electroporation (i.e., electrotransfection), microinjection, gene gun methods, or virus-mediated methods (such as adenovirus infection, lentivirus infection).

[0071] The anti-group A rotavirus monoclonal antibodies described in this article can be murine monoclonal antibodies, humanized monoclonal antibodies (including chimeric antibodies, CDR transplantation antibodies, and SDR transplantation antibodies), or fully human monoclonal antibodies.

[0072] The monoclonal antibody against group A rotavirus described in this article can bind to the VP8* protein of various group A rotaviruses (including six genotypes such as P[1], P[6], P[7], P[8], P

[13] , and P

[23] ), and has the effect of neutralizing group A rotavirus. It is also known as a broad-spectrum neutralizing monoclonal antibody against group A rotavirus.

[0073] The monoclonal antibody of the present invention can be prepared by various methods known in the art, such as through genetic engineering recombination technology. For example, DNA molecules encoding the heavy and light chain genes of the monoclonal antibody of the present invention can be obtained by chemical synthesis or PCR amplification. The obtained DNA molecule is inserted into an expression vector, then transfected into host cells, and the transfected host cells are cultured under suitable conditions to express the monoclonal antibody of the present invention. Those skilled in the art can select conventional host cells, expression vectors, methods for introducing the expression vector into host cells, and antibody isolation and purification methods as needed.

[0074] This invention screened and identified a broad-spectrum neutralizing monoclonal antibody against group A rotavirus using hybridoma technology, named TAH028. Experimental results showed that the monoclonal antibody TAH028 could react with various genotypes of porcine group A rotavirus (PoRVA) strains (including G3P

[23] , G5P

[23] , G4P

[13] , G9P

[23] , and G5P

[13] types); it could recognize the VP8* protein of six genotypes of group A rotavirus, including the VP8* protein of porcine group A rotavirus (PoRVA) types P[6], P[7], P

[23] , and P

[13] , as well as the VP8* protein of bovine group A rotavirus (BRVA) type P[1] and human group A rotavirus (HRVA) type P[8]. Indirect immunofluorescence assay results showed that the monoclonal antibody TAH028 of this invention has good neutralizing ability and can neutralize different genotypes of rotavirus strains. The detection of rotavirus using the monoclonal antibody TAH028 of this invention via ELISA is highly consistent with conventional neutralization assays. The neutralization titer can be rapidly determined based on the OD value, making it suitable for high-throughput detection of rotavirus serum antibodies.

[0075] In summary, the monoclonal antibody TAH028 of this invention can be expressed and produced in prokaryotic cells, eukaryotic cells, and any recombinant system, and can be formulated into diagnostic reagents and products for clinical use in rotavirus. The monoclonal antibody TAH028 of this invention can react with a variety of rotaviruses, exhibiting a broader spectrum compared to other rotavirus monoclonal antibodies. It can recognize six genotypes of group A rotavirus, namely P[1], P[6], P[7], P[8], P

[13] , and P

[23] , and possesses excellent neutralizing ability. It is the first broad-spectrum neutralizing monoclonal antibody against six rotavirus genotypes obtained. The monoclonal antibody TAH028 provided by this invention, as well as the diagnostic reagents and products developed based on this antibody, can be used for serological diagnosis of rotavirus, evaluation of immunogenicity, and detection of rotavirus pathogens in experimental serum products, etc., and has broad application prospects in clinical diagnosis and other fields.

[0076] Terminology Definition In this invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, to better understand this invention, definitions and explanations of relevant terms are provided below.

[0077] The term "antigen-binding fragment" generally refers to a functional segment of an antibody structure that can bind to an antigen, typically comprising at least a portion of the antigen-binding region or variable region (e.g., one or more CDRs) of the parent antibody. The antigen-binding fragment retains at least some of the binding specificity of the parent antibody. Typically, when activity is expressed on a molar basis, the antigen-binding fragment retains at least 10% of the parent antibody's binding activity. Specifically, the antigen-binding fragment retains at least 20%, 50%, 70%, 80%, 90%, 95%, or 100% or more of the parent antibody's binding affinity to the target. Those skilled in the art will recognize that the antigen-binding fragment can be generated by recombinant DNA technology or by enzymatic or chemical cleavage of the intact antibody. Antigen-binding fragments include, but are not limited to, Fab, Fab′, F(ab′)2, antibody variable regions (Fv), disulfide-stabilized Fv (dsFv), single-domain antibodies (SdAb), single-chain antibodies (ScFv), minibody antibodies, and minimum recognition units (MRUs).

[0078] The term "nanobody" is also known as a single-domain antibody (sdAb), which usually refers to an antibody consisting of only one H chain V region, and can also be called a VHH antibody.

[0079] The term "Fab" refers to a "Fab antibody," which is typically a heterodimer composed of a heavy chain (Fd) and a complete light chain linked by disulfide bonds, containing only one antigen-binding site. By linking the coding genes for the heavy chain Fd and the complete light chain and fusing them with a bacterial protein signal peptide gene, Fab antibodies can be secreted and expressed in *E. coli*, exhibiting complete stereofolding and intra- and inter-chain disulfide bonds. The heavy chain Fd refers to approximately half of the H chain portion of the Fab (including VH, CH1, and part of the hinge region).

[0080] The term "Fab′" refers to "Fab′ antibody" or "Fab′ fragment," and typically refers to a portion containing a light chain and a heavy chain containing the VH domain, the CH1 domain, and the region between the CH1 and CH2 domains.

[0081] The term "F(ab′)2" typically refers to a heavy chain containing two light chains and two heavy chains containing constant regions between CH1 and CH2 domains, thereby forming interchain disulfide bonds between the two heavy chains. Therefore, the F(ab′)2 segment consists of two Fab′ segments held together by disulfide bonds between the two heavy chains.

[0082] The term "Fv" refers to "Fv antibody," which typically refers to a small functional fragment of an antibody molecule that retains the antigen aggregation site. It consists of VH and VL genes, linked non-covalently. Vectors containing both VH and VL genes can be constructed separately, co-transfected into cells for expression, and then assembled into functional Fv antibodies. Alternatively, a stop codon can be placed between the VH and VL genes in the vector to express two small protein fragments, which are then linked non-covalently to form Fv antibodies.

[0083] The term "disulfide-stable Fv (dsFv)" generally refers to a stable Fv formed by connecting fixed backbone regions in VH and VL through intra-chain or inter-chain disulfide bonds.

[0084] The term "minibody" typically refers to a fusion protein formed by linking the C-terminus of an scFv to the CH3 group of human IgG. This fusion protein can spontaneously form a stable, covalently bound bivalent antibody within the cell, structurally resembling a "short" version of a complete antibody molecule. Minibodies can achieve the polymerization of two peptide chains in two ways: one is by using a short linker peptide, where the minibody polymerizes entirely through CH3 self-polymerization; the other is by using a flexible, long peptide chain with multiple disulfide bonds introduced in the middle to stabilize the dimer structure of the minibody.

[0085] The term "single-chain antibody (ScFv)" generally refers to an antibody that expresses a single polypeptide chain by linking the light and heavy chain variable regions of a gene with an appropriate oligonucleotide linker. The polypeptide chain can spontaneously fold into its natural construct, maintaining the specificity and affinity of the Fv.

[0086] The term "minimum recognition unit (MRU)" typically refers to a single CDR structure containing only the variable region, with a molecular weight of only about 1% of that of a complete antibody, which can bind to the corresponding antigen.

[0087] The term "CDR (Complementarity Determining Region)" generally refers to the amino acid residues in the variable region of an antibody responsible for antigen binding. CDRs can be defined according to various numbering systems known in the art, such as the Kabat numbering system, the Chothia numbering system, or the IMGT numbering system. For a given antibody, those skilled in the art can readily identify the CDR as defined by each numbering system. Furthermore, the correspondence between different numbering systems is well known to those skilled in the art.

[0088] The term "framework region (FR)" generally refers to the amino acid residues in the antibody variable region other than the CDR residues as defined above.

[0089] The term "immunosensor" generally refers to a device that immobilizes antigens or antibodies on the surface of a solid support, combining specific immune responses with highly sensitive sensing technology to monitor antigen-antibody reactions, thereby detecting antigens or antibodies in a sample. Immunosensors achieve quantitative detection and real-time monitoring, making them a quantitative and automated immunoassay and diagnostic product.

[0090] The term "diagnosis" generally refers to a method for determining whether a subject is likely to have a given disease or condition, including but not limited to diseases or conditions characterized by antigens or pathogens. Technicians typically make diagnoses based on one or more diagnostic indicators whose presence, absence, quantity, or change in quantity indicates the presence, severity, or absence of a disease or condition. Other diagnostic indicators may include patient history; physical symptoms, etc.

[0091] The term "neutralizing antibody" generally refers to an antibody that can bind to antigens on the surface of pathogenic microorganisms, thereby preventing the pathogenic microorganisms from adhering to target cell receptors and preventing them from invading cells.

[0092] The term "comprising" is not intended to be restrictive, but rather inclusive and implies the possible presence of other elements besides those listed; it can be interpreted as "including but not limited to". The term "comprising" also encompasses the terms "consisting of" and "substantially consisting of". In this document, the terms "comprising" and "including" are used interchangeably. Attached Figure Description

[0093] Figure 1 The results are from an indirect immunofluorescence assay of monoclonal antibody TAH028 with different genotypes of PoRVA strains.

[0094] Figure 2 The results of Western blot experiments on monoclonal antibody TAH028 and VP8* protein of different genotype RVA strains are presented.

[0095] Figure 3 The results of SDS-PAGE assay to identify the purification effect of monoclonal antibody TAH028.

[0096] Figure 4 The results show the ability of monoclonal antibody TAH028 to neutralize the PoRVA strain.

[0097] Figure 5 The results are from an immunoblotting experiment showing the expression of the monoclonal antibody TAH028. Detailed Implementation

[0098] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.

[0099] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available.

[0100] The E. coli expression vector pET-28a(+) in the following examples is described in the following literature: Xu Jiachao, Hu Guangli, Wu Qingqing, et al. Preparation of polyclonal antibody against porcine group A rotavirus VP8* protein and determination of its neutralizing antibody titer [J]. Chinese Journal of Veterinary Medicine, 2025(6). It is available to the public from the applicant to repeat the experiments of this application.

[0101] The PoRVA strains of various genotypes isolated and preserved in this laboratory in the following examples (PoRVA-XJT10-G3P

[23] , PoRVA-XJT11-G5P

[23] and PoRVA-XJT1-G4P

[13] ), as well as PoRVA-KY-G9P

[23] and PoRVA-XN-G5P

[13] , are described in the following literature: Xu Jiachao, Hu Guangli, Wu Qingqing, et al. Preparation of polyclonal antibody against VP8* protein of porcine group A rotavirus and determination of its neutralizing antibody titer [J]. Chinese Journal of Veterinary Medicine, 2025, 45(6):1109-1116+1131.DOI:10.16303 / j.cnki.1005-4545.2025.06.02. The public may obtain the biological material from the applicant in accordance with the relevant provisions of national biosafety to repeat the experiments of this application.

[0102] The MA-104 cells used in the following examples are products of CyberKang, catalog number: iCell-c013.

[0103] Example 1: Preparation and Identification of Monoclonal Antibodies Against Rotavirus VP8* Protein In this embodiment, the immune antigens are the VP8* protein of the XJWF1 strain (G9P

[23] ) of porcine group A rotavirus (PoRVA) (abbreviated as PoRVA-XJWF1 VP8* protein) and the VP8* protein of the ShXYW13 strain (G5P

[13] ) of porcine group A rotavirus (PoRVA) (abbreviated as PoRVA-ShXYW13 VP8* protein). In this embodiment, the *E. coli* expression system was used to prepare PoRVA-XJWF1 VP8* and PoRVA-ShXYW13 VP8* proteins. The specific steps are as follows: The coding gene of PoRVA-XJWF1 VP8* protein (nucleotide sequence is SEQ ID No. 9) and the coding gene of PoRVA-ShXYW13 VP8* protein (SEQ ID No. 10) were cloned into the 3' end of the sequence with His tags (the nucleotide sequence of the His tag is 5'-CATCATCACCATCACCAT-3', SEQ ID No. 11), respectively, to obtain recombinant expression vectors. The above recombinant expression vectors were transformed into DH5α competent cells to obtain recombinant vectors containing the target gene fragments, which were named pET-XJWF1 VP8* and pET-ShXYW13 VP8*, respectively. The recombinant vectors pET-XJWF1 VP8* and pET-ShXYW13 VP8* were transformed into Escherichia coli BL21(DE3) competent cells for protein expression. The PoRVA-XJWF1 VP8* and PoRVA-ShXYW13 VP8* proteins were collected by fixed metal ion affinity chromatography and purified to obtain the immunoantigens, namely PoRVA-XJWF1 VP8* and PoRVA-ShXYW13 VP8* proteins.

[0104] 1. Immunizing mice SPF-grade female BALB / c mice aged 6-8 weeks were immunized. PoRVA-XJWF1 VP8* protein and PoRVA-ShXYW13 VP8* protein were emulsified with an equal volume of 201 adjuvant (Seppic Company) and injected subcutaneously at multiple sites. Each mouse was immunized with 50 μg of antigen protein every two weeks. The first immunization was with PoRVA-XJWF1 VP8* protein, the second immunization was with PoRVA-ShXYW13 VP8* protein, and the third immunization was with an equal mixture of PoRVA-XJWF1 VP8* protein and PoRVA-ShXYW13 VP8* protein (25 μg each). A total of 3 immunizations were performed. One week after the third immunization, 100 μg of unadjuvanted PoRVA-XJWF1 VP8* protein and PoRVA-ShXYW13 VP8* protein (50 μg each) were injected intraperitoneally for shock immunization. The mice were then fed for another 3 days.

[0105] 2. Cell fusion and hybridoma cell screening Cell fusion: Three days after the initial immunization, mice were euthanized by dislocation, and the spleen was removed and gently crushed in a nylon sieve. The spleen was washed with sterile PBS, and the washings were collected. Red blood cells were removed using erythrocyte lysis buffer, and the spleen cells were counted. SP2 / 0 cells were mixed with spleen cells at a 1:5 ratio and centrifuged at 1200 r / min for 3 min. The supernatant was discarded, and the pellet was washed twice with 10 mL of electrofusion buffer (BTX), then resuspended in 9 mL of electrofusion buffer. The cells were transferred to an electrofusion apparatus for fusion, with the fusion parameters set to 800V, 40 μs, and 1 cycle. After fusion, the cells were activated for 10 h in RPMI-1640 complete medium containing 5% FBS and then transferred to HY semi-solid medium for 10 days of culture.

[0106] Hybridoma cell screening: Monoclonal cell clusters from HY semi-solid medium were transferred to HAT medium and cultured for 3 days. Indirect immunofluorescence assays were used to screen antibody-positive wells. After subcloning, a hybridoma cell line capable of secreting a monoclonal antibody specifically binding to VP8* protein was identified and named TAH028. The monoclonal antibody secreted by hybridoma cell line TAH028 is called monoclonal antibody TAH028.

[0107] 3. Identification of the type of reaction between monoclonal antibodies and viruses The monoclonal antibody TAH028 was used in an indirect immunofluorescence assay (IFA) with various genotypes of the popular PoRVA strains (PoRVA-XJT10-G3P

[23] , PoRVA-XJT11-G5P

[23] and PoRVA-XJT1-G4P

[13] ) isolated and preserved in our laboratory, as well as a G9P

[23] strain (PoRVA-KY-G9P

[23] ) and a G5P

[13] strain (PoRVA-XN-G5P

[13] ) donated by Professor Cao Yongchang of the School of Life Sciences, Sun Yat-sen University. The specific steps are as follows: ① Cell preparation: Culture MA-104 cells in 96-well cell culture plates. Before inoculation, the cell confluence should be >90%.

[0108] ② Cell inoculation: Dilute the cytotoxic agent to 2000 TCID using trypsin working solution containing 5 μg / mL trypsin. 50 / mL, then inoculate 100 μL / well into a 96-well plate and incubate at 37°C, 5% CO2 for 1 h.

[0109] ③ Cell fixation: After incubation, discard the cell culture supernatant, add 200 μL PBS to each well of a 96-well plate and wash three times, then add 50 μL of 80% cold acetone stored at -20℃ and fix in a -20℃ freezer for 1 h.

[0110] ④ Primary antibody incubation: Discard the cold acetone fixative, add 200 μL of PBS to each well and wash 3 times, then add 100 μL of hybridoma cell culture supernatant to each well and incubate at 37℃ for 1 h.

[0111] ⑤ Secondary antibody incubation: Discard the primary antibody incubation solution, add 200 μL of PBS to each well and wash 3 times. Dilute the Alexa Fluor 488 fluorescent secondary antibody 1:500 with PBS, and add 0.01% Evans Blue and 5% FBS. Mix thoroughly and add 100 μL to each well of the cell plate. Incubate at 37°C for 1 h.

[0112] ⑥ Fluorescence observation: Discard the secondary antibody incubation solution, add 200 μL of PBS to each well and wash 3 times, then observe the reaction between the antibody and infected cells under a fluorescence microscope.

[0113] The results are as follows Figure 1 As shown, the monoclonal antibody TAH028 reacted with all strains and exhibited significant fluorescence.

[0114] The VP8* protein of different genotypes of PoRVA was expressed by the Escherichia coli expression system, including the VP8* protein of the following four PoRVA (Porcine Group A Rotavirus) strains: 14226_39-P[6], F37-P[7], XJJY1-P

[23] , and NMBB10-P

[13] . The VP8* protein of a BRVA (bovine group A rotavirus) strain QH1-P[1]; The VP8* protein of HRVA (human group A rotavirus) strain 16020_35-P[8].

[0115] The preparation methods for the VP8* proteins of the above six strains are the same as those for the preparation of PoRVA-XJWF1 VP8* proteins and PoRVA-ShXYW13 VP8* proteins in Example 1. The encoding genes for each VP8* protein cloned into the E. coli expression vector pET-28a(+) are as follows: The nucleotide sequence of the gene encoding the VP8* protein 14226_39-P[6] is shown in SEQ ID No.12.

[0116] The nucleotide sequence of the gene encoding the F37-P[7]VP8* protein is shown in SEQ ID No. 13.

[0117] The nucleotide sequence of the gene encoding the XJJY1-P

[23] VP8* protein is shown in SEQ ID No.14.

[0118] The nucleotide sequence of the gene encoding the NMBB10-P

[13] VP8* protein is shown in SEQ ID No. 15.

[0119] The nucleotide sequence of the gene encoding the QH1-P[1]VP8* protein is shown in SEQ ID No. 16.

[0120] The nucleotide sequence of the gene encoding the VP8* protein 16020_35-P[8] is shown in SEQ ID No.17.

[0121] The monoclonal antibody TAH028 was subjected to Western blot experiments with different genotypes of PoRVA, BRVA, and HRVAVP8* proteins expressed through the E. coli expression system (i.e., the VP8* proteins of the above six strains, as well as PoRVA-XJWF1 VP8* and PoRVA-ShXYW13 VP8* proteins). The protein-tagged antibody anti-His Tag mAb (Solepro's product, catalog number: K200060M) was used as a control. The specific steps are as follows: ① Protein treatment: Add VP8* protein to 4× loading buffer in proportion and boil for 10 min.

[0122] ② Protein electrophoresis: The processed protein (10 μL per lane) was loaded into a 10% SDS-PAGE gel for electrophoresis. The electrophoresis program was 55 V for 50 min and 110 V for 80 min.

[0123] ③ Transfer: After electrophoresis, the proteins in the gel are transferred to the NC membrane (nitrocellulose membrane) using a semi-dry transfer method, with a program of 23 V-25 min.

[0124] ④ Blocking: Add 5 g of skim milk powder to every 100 mL of PBS and shake thoroughly to prepare the blocking solution. Add 5 mL of the blocking solution to a resealable bag and place it on a shaker at room temperature to block the NC membrane for 1 h.

[0125] ⑤ Incubation with primary antibody: Dilute hybridoma cell culture supernatant with blocking buffer at 1:100, and use Anti-His Tag antibody diluted at 1:3000 as a positive control. Incubate overnight at 4°C on a shaker.

[0126] ⑥ Incubation with secondary antibody: Discard the primary antibody, wash the membrane 3 times with PBS, add Alexa Fluor 680-labeled fluorescent secondary antibody diluted 1:5000 with PBS, and incubate on a shaker at room temperature in the dark for 1 h.

[0127] ⑦ Scan the NC membrane: Discard the secondary antibody, wash the membrane three times with PBS, place it in a two-color infrared laser imaging system for scanning and save the image.

[0128] The results are as follows Figure 2 As shown, the monoclonal antibody TAH028 reacted with the VP8* protein of all strains.

[0129] Figure 2 In the middle: P

[23] -XJWF1 represents the PoRVA-XJWF1 VP8* protein; P

[23] -XJJY1 represents XJJY1-P

[23] VP8* protein; P

[13] -NMBB10 represents NMBB10-P

[13] VP8* protein; P

[13] -ShXYW13 represents the PoRVA-ShXYW13 VP8* protein; P[1] represents QH1-P[1]VP8* protein; P[6] represents the 14226_39-P[6]VP8* protein; P[7] represents F37-P[7]VP8* protein; P[8] represents the 16020_35-P[8]VP8* protein.

[0130] 4. Preparation and purification of ascites fluid from monoclonal antibodies Female Balb / C mice (6-8 weeks old) were intraperitoneally injected with 300 μL of mouse ascites adjuvant, followed by an intraperitoneal injection of 1×10⁻⁶ mol / L of adjuvant 12 days later. 6 TAH028 hybridoma cells were used to extract ascites fluid from mice after significant abdominal swelling. The fluid was centrifuged at 12000 r / min for 10 min, and the supernatant was collected and stored. Antibodies in the ascites fluid were purified using a Protein A / G pre-packed column, and the purification effect was verified by SDS-PAGE. The results are shown below. Figure 3 As shown, there is a clear and single band at a value greater than 180 kDa, indicating that the experiment yielded a high-purity monoclonal antibody TAH028.

[0131] 5. Neutralizing capacity assessment of monoclonal antibody TAH028 The ability of monoclonal antibody TAH028 to neutralize PoRVA P

[13] strain XJT1 (PoRVA-XJT1-G4P

[13] ) and PoRVA P

[23] strain KY (PoRVA-KY-G9P

[23] ) was determined by indirect immunofluorescence assay. The determination method is as follows: PoRVA strains of different genotypes (PoRVA-XJT1-G4P

[13] and PoRVA-KY-G9P

[23] ) were diluted to 2000 TCID using trypsin working solution containing 5 μg / mL trypsin. 50 / mL, add 50 μL of virus dilution to a 96-well plate. The purified antibody TAH028 is serially diluted 2-fold using trypsin working solution containing 5 μg / mL trypsin. For each concentration gradient, add 50 μL to the corresponding virus solution and incubate at 37°C for 1 h to obtain the virus / antibody neutralization solution. Wash the 96-well MA-104 cells twice with PBS (200 μL / well). Before inoculation, the confluence of MA-104 cells should be >90%. Add the obtained virus / antibody neutralization solution (100 μL / well) to the 96-well MA-104 cells and incubate at 37°C and 5% CO2 for 48 h. Use IFA to determine whether the broad-spectrum rotavirus monoclonal antibody TAH028 can neutralize different rotavirus genotypes.

[0132] The results are as follows Figure 4 As shown, when a higher concentration of purified monoclonal antibody TAH028 was added, cells infected with P

[13] or P

[23] strains showed no obvious green fluorescence. As the antibody dilution factor increased, cells infected with different strains showed green fluorescence, indicating that monoclonal antibody TAH028 has good neutralizing ability.

[0133] 6. Sequence of monoclonal antibody TAH028 The purified monoclonal antibody TAH028 was sequenced by Nanjing Detai Biotechnology Co., Ltd. Based on the nucleic acid sequence obtained through Sanger sequencing, the corresponding amino acid sequence was obtained using the rule that a triplet codon encodes one amino acid. The final sequence of monoclonal antibody TAH028 is as follows: The amino acid sequence of the heavy chain variable region (VH) of monoclonal antibody TAH028 is shown below (the three underlined parts are CDR1, CDR2 and CDR3 in order): QVQLQQSGPELARPGASVKMSCKAS GYALTAYW IHWVKQRPGQGLEWIGF INPNTDYA DYNQNFKDKATLTADKSSNTAFMQLNSLTSEDSALYYC ARSAVDYW GQGTTLTVSS (SEQ ID No. 1).

[0134] in: The amino acid sequence of the heavy chain variable region CDR1 of monoclonal antibody TAH028 is located at positions 27-38 of the IMGT; among which, positions 31-34 of the IMGT are deletion sites, and its amino acid sequence is GYALTAYW (SEQ ID No. 18, i.e. positions 26-33 of SEQ ID No. 1). The amino acid sequence of the heavy chain variable region CDR2 of monoclonal antibody TAH028 is located at position 56-65 of IMGT; among which IMGT positions 60 and 61 are deletion sites, and its amino acid sequence is INPNDYA (SEQ ID No. 19, i.e. positions 51-58 of SEQ ID No. 1). The amino acid sequence of the heavy chain variable region CDR3 of monoclonal antibody TAH028 is located at position 105-117 of IMGT; among which IMGT position 109-114 is a deletion site, and its amino acid sequence is ARSAVDYW (SEQ ID No. 20, i.e. positions 97-104 of SEQ ID No. 1).

[0135] The nucleotide sequence of the gene encoding the heavy chain variable region of monoclonal antibody TAH028 is shown below: 5'-CAGGTCCAGCTTCAGCAGTCTGGGCCTGAACTGGCAAGACCTGGGGCCTCAGTGAAGATGTCCTGCAAGGCTTCTGGCTACGCCTTAACTGCCTACTGGATACACTGGGTCAAACAGAGGCCTGGACAGGGTCTGGAATGGATTGGATTCATTAATCCTAACACTGATTATGC TGACTACAATCAGAACTTCAAGGACAAGGCCACATTGACTGCAGACAAATCCTCCAATACAGCCTTCATGCAACTGAACAGCCTGACGTCTGAGGACTCTGCACTCTATTACTGTGCAAGATCCGCCGTTGATTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA-3' (SEQ ID No.2).

[0136] The amino acid sequence of the light chain variable region (VL) of monoclonal antibody TAH028 is shown below (the three underlined parts are CDR1, CDR2, and CDR3 in order): DVVMIQTPLTLSVIIGQPASISCKSS QSLLNSAGKTY LNWLLQRPGQSPKRLIY EVSKLDSGVPDRFTGSGSGTDFTLEISRVEAEDLGVYFC WQGTHFPWT FGGGTKLEIK (SEQ ID No. 3).

[0137] in: The amino acid sequence of the CDR1 variable region of the light chain of monoclonal antibody TAH028 is located at position 27-38 of the IMGT; among which, IMGT position 33 is a deletion site, and its amino acid sequence is QSLLNSAGKTY (SEQ ID No. 21, i.e. positions 27-37 of SEQ ID No. 3). The amino acid sequence of the CDR2 variable region of the light chain of monoclonal antibody TAH028 is located at positions 56-65 of the IMGT; among which, IMGT positions 58, 59, 60, 61, 62, 63 and 64 are deletion sites, and their amino acid sequence is EVS (positions 55-57 of SEQ ID No. 3). The amino acid sequence of the CDR3 light chain variable region of monoclonal antibody TAH028 is located at position 105-117 of IMGT; among which IMGT positions 110, 111, 112, and 113 are deletion sites, and its amino acid sequence is WQGTHFPWT (SEQ ID No. 22, i.e. positions 94-102 of SEQ ID No. 3).

[0138] The nucleotide sequence of the gene encoding the light chain variable region of monoclonal antibody TAH028 is shown below: 5'-GATGTTGTGATGATCCAGACTCCACTCACTTTGTCGGTTATCATTGGACAACCAGCCTCCATCTCTTGCAAGTCAAGTCAGAGCCTCTTAAATAGTGCTGGCAAGACATATTTGAATTGGTTGTTACAGAGGCCAGGCCAGTCTCCAAAGCGCCTCATCTATGAGGTGTC TAAACTGGACTCTGGAGTCCCTGACAGGTTCACTGGCAGTGGATCAGGGACAGATTTCACACTGGAAATCAGCAGAGTGGAGGCTGAGGATTTGGGAGTTTATTTTTGCTGGCAAGGTACACATTTTCCGTGGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA-3' (SEQ ID No.4).

[0139] The sequence of complementary determination regions is defined according to the IMGT numbering system.

[0140] 7. Preparation of antibodies using genetic engineering methods (1) Construction of recombinant expression plasmid To express the monoclonal antibody TAH028, heavy chain expression vectors and light chain expression vectors were prepared respectively: The nucleotide sequence of the heavy chain gene of monoclonal antibody TAH028 was obtained by directly linking the nucleotide sequence of the gene encoding the variable region of the heavy chain (SEQ ID No. 2) with the mouse-IgG2a template sequence (the constant region sequence of the heavy chain, SEQ ID No. 5). The amino acid sequence of the constant region of the heavy chain of monoclonal antibody TAH028 is shown in SEQ ID No. 6.

[0141] The nucleotide sequence of the light chain gene of monoclonal antibody TAH028 was obtained by directly linking the nucleotide sequence of the light chain variable region encoding gene (SEQ ID No. 4) with the mouse-kappa template sequence (light chain constant region sequence, SEQ ID No. 7). The amino acid sequence of the light chain constant region of monoclonal antibody TAH028 is shown in SEQ ID No. 8.

[0142] The heavy chain gene and light chain gene of monoclonal antibody TAH028 were cloned into vector pcDNA3.4, respectively, to obtain heavy chain expression vector and light chain expression vector. The recombinant vectors were synthesized by Nanjing Detai Biotechnology Co., Ltd.

[0143] (2) Antibody expression Antibodies were expressed using the RapidTransCHO Expression Kit (Shanghai Beianji Biotechnology Co., Ltd., TP0301301). All reagents used in this step were components of the kit. a) Take 100 mL of CHO-K1 cells that have been passaged no more than 20 times and are in the mid-exponential growth phase, with a viability greater than 90%. Dilute the viable cells to 3–4 × 10⁻⁶ using RapidTransCHO expression medium V2 (Shanghai Bei'anji Biotechnology Co., Ltd., TP0301301). 6 After culturing for 19–26 hours, cell density and viability were measured at 7–10 × 10⁶ cells / mL. 6 When the cell count / mL and viability are 95%–99%, dilute with the same culture medium to 6 × 10⁻⁶. 6 cells / mL, for later use.

[0144] b) On the day of transfection, take 1 / 10 of the initial transfection volume of RapidTransCHO expression medium and dilute the plasmid DNA and transfection reagent separately: add 1 μg of total DNA (containing 0.5 μg each of light chain and heavy chain expression plasmids) to each mL of initial transfection volume, and add 8 μL of RapidTrans transfection reagent V2 to each mL of initial transfection volume. After mixing well, slowly add the diluted transfection reagent to the diluted DNA, mix by inverting, and let stand at room temperature for 10-15 minutes to form the transfection reagent / plasmid DNA complex.

[0145] c) Slowly add the above complex to the cell suspension prepared in step a), mix gently, and incubate in a shaker at 37°C, 5%–8% CO2, saturated humidity, and 115–135 rpm (50 mm wheelbase).

[0146] d) On day 1 post-transfection (18-22 hours), add 8% RapidTransCHO aV2, 0.8% RapidTransCHO bV2 and 2% RapidTransCHO enhancer V2 according to the initial transfection volume, and at the same time lower the temperature to 32℃ and continue culturing.

[0147] e) On day 3 post-transfection, add 16% RapidTransCHO a V2 and 1.6% RapidTransCHO b V2 according to the initial transfection volume, and continue culturing at 32°C.

[0148] f) On day 7 post-transfection, add 8% RapidTransCHO a V2 and 0.8% RapidTransCHO b V2 according to the initial transfection volume, and continue incubation at 32°C.

[0149] g) On days 8-9 after transfection, collect the cell culture, centrifuge at 4000-5000×g for 30 minutes, and collect the supernatant for antibody purification or detection.

[0150] (3) Verification of antibody expression Collect the cell expression supernatant, add non-reducing buffer without DTT in the specified ratio, and load it for Western blot experiments. The results are as follows: Figure 5 As shown, samples treated with standard loading buffer exhibited distinct bands above 180 kDa, while samples treated with loading buffer containing β-mercaptoethanol showed single bands at 25 kDa and 50 kDa, respectively. These results indicate high monoclonal antibody purity and good purification efficiency; the loading buffer containing β-mercaptoethanol successfully reduced the antibody to the light chain (25 kDa) and heavy chain (50 kDa). These experiments demonstrate successful antibody expression.

[0151] (4) Antibody purification a) Buffer preparation: Add Na2HPO4·12H2O to sterile ddH2O to make a final concentration of 0.2 M, and shake thoroughly to mix.

[0152] b) Preparation of pre-elution buffer: Add 0.1 M citric acid to the buffer prepared in step a) to make the volume percentage of citric acid 20%.

[0153] c) Preparation of elution buffer: Add 0.1 M citric acid to the buffer prepared in step a) to make the volume percentage of citric acid 60%.

[0154] d) Sample processing: Take 30 mL of the cell expression supernatant verified in step (3), add the buffer solution prepared in step a) at a volume ratio of 1:1, filter with a pore size of 0.22 μm to obtain the sample solution, and prepare for column loading.

[0155] e) Equilibrate the column: Use a constant flow pump to slowly pass 10 mL of buffer solution through a pre-packed Protein A / G4FF column (Sangon Biotech, C600983) at a flow rate of 1 mL / min.

[0156] f) Sample loading: The sample solution obtained in step d) was slowly passed through the Protein A / G column at a flow rate of 1 mL / min using a constant flow pump.

[0157] g) Washing: Using a constant flow pump, slowly pass 10 mL of washing buffer (i.e., the buffer prepared in step a) through the Protein A / G column at a flow rate of 1 mL / min.

[0158] h) Pre-elution: 10 mL of pre-elution solution was slowly passed through the Protein A / G column at a flow rate of 1 mL / min using a constant flow pump.

[0159] i) Elution: 15 mL of eluent was slowly passed through the Protein A / G column at a flow rate of 1 mL / min using a constant flow pump, and the elution product was aliquoted into 1.5 mL centrifuge tubes.

[0160] Example 2: Preparation of conjugated antibodies HRP was conjugated to monoclonal antibody TAH028 using an HRP conjugation kit (Sangon Biotech (Shanghai) Co., Ltd., catalog number: D601047). The specific steps are as follows: 1) Mix 500 μL of HRP solution with 200 μL of HRP activation buffer, place on a shaker and shake slowly for 30 min at room temperature.

[0161] 2) Add 200 μL of HRP coupling buffer and let stand at room temperature for 30 min.

[0162] 3) Add 1 mL of purified monoclonal antibody TAH028 (obtained by step (4) in step 7 of Example 1, antibody preparation using genetic engineering method), and transfer it to a dialysis bag. Dialyze in 2 L of dialysis solution at room temperature for 2 h.

[0163] 4) Add 100 μL of reducing agent to the dialysis product, let it stand at room temperature for 2 h, stir once every 30 min, dispense and store the coupling product.

[0164] Example 3: Establishment of a method for detecting rotavirus blocking ELISA antibodies This embodiment exemplarily establishes an ELISA method for detecting rotavirus using the monoclonal antibody TAH028. The specific operation method is as follows: (1) Coat the microplate with PoRVA-XJWF1 VP8* protein (prepared in Example 1), discard the coating solution after coating, and seal the plate under vacuum.

[0165] (2) Add 50 μL of sample diluent to each well of the coated plate, and then add the serum sample to be tested to the corresponding well. The samples are 138 diarrhea samples from piglets and nursery pigs. Incubate at 37℃ for 1 h.

[0166] (3) Discard the liquid in each well and wash the wells with 300 μL of washing solution for a total of 5 times. After the last wash, pat the washing solution in the air dry.

[0167] (4) Add 100 μL of diluted HRP-TAH028 conjugate antibody to each well and incubate at 37°C for 1 h.

[0168] (5) Repeat step (3).

[0169] (6) Add 50 μL of TMB colorimetric solution to each well and incubate at room temperature in the dark for 10 min.

[0170] (7) Add 50 μL of stop solution to each well to terminate the reaction, and measure the OD using an enzyme-linked immunosorbent assay (ELISA) reader. 450 value.

[0171] Following the method described in Example 1, section 5, regarding the neutralizing capacity identification of monoclonal antibody TAH028, 20 porcine serum samples were used for a rotavirus neutralization test. Laboratory-preserved rotavirus inactivated vaccine-immunized serum was used as a positive control (PC), and unimmunized SPF porcine serum was used as a negative control (NC). Simultaneously, a blocking ELISA method was used to detect rotavirus-specific antibodies in the serum, the blocking rate was calculated, and compared with the neutralization test results. Neutralization test results: Of the 20 serum samples, 15 were positive and 5 were negative (neutralizing titer <1:16). Among the positive sera: sera 3, 9, and 17 were high-titer positive (≥1:1024), totaling 3 samples; sera 1, 6, 11, 14, and 19 were medium-titer positive (1:128–1:512), totaling 5 samples; and sera 2, 5, 8, 10, 13, 15, and 18 were low-titer positive (1:32–1:64), totaling 7 samples. The neutralizing titers in negative serum were all <1:16.

[0172] ELISA blocking results: The OD value of the positive control PC was 0.05, and the OD value of the negative control NC was 0.92. The blocking rate for each serum sample was calculated using the generally accepted formula: Blocking rate = (Negative control OD value - Sample OD value) / (Negative control OD value - Positive control OD value) * 100%. Serum samples 3, 9, and 17 showed strong neutralization / high blocking: OD values ​​ranged from 0.06 to 0.10, with blocking rates of 94.3% to 100%; samples 1, 6, 11, 14, and 19 showed weak neutralization / moderate blocking: OD values ​​ranged from 0.15 to 0.30, corresponding to blocking rates of 88.5% to 71.3%; serum samples 2, 5, 8, 10, 13, 15, and 18 showed low blocking: OD values ​​ranged from 0.35 to 0.50, corresponding to blocking rates of 65.5% to 48.3%. The results are shown in Table 1. The results of the blocking ELISA were completely consistent with those of the neutralization test. All 15 positive sera showed varying degrees of blocking activity, while all 5 negative sera showed low blocking (no neutralizing ability). The concordance rate between the two methods was 100%.

[0173]

[0174] The above results indicate that the blocking ELISA method of the present invention is highly consistent with the conventional neutralization test, and can quickly determine the neutralization titer level based on the OD value, making it suitable for high-throughput detection of rotavirus serum antibodies.

[0175] The present invention has been described in detail above. Those skilled in the art will recognize that the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. While specific embodiments have been provided, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein.

Claims

1. Anti-group A rotavirus monoclonal antibody or antigen-binding fragment thereof, characterized in that, The monoclonal antibody or its antigen-binding fragment comprises VHCDR1 with the amino acid sequence GYALTAYW (SEQ ID No. 18), VHCDR2 with the amino acid sequence INPNDYA (SEQ ID No. 19), VHCDR3 with the amino acid sequence ARSAVDYW (SEQ ID No. 20); and VLCDR1 with the amino acid sequence QSLLNSAGKTY (SEQ ID No. 21), VLCDR2 with the amino acid sequence EVS, and VLCDR3 with the amino acid sequence WQGTHFPWT (SEQ ID No. 22).

2. The monoclonal antibody or antigen-binding fragment thereof according to claim 1, characterized in that, The monoclonal antibody or its antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region being shown in SEQ ID No. 1, and the amino acid sequence of the light chain variable region being shown in SEQ ID No.

3.

3. A biomaterial, characterized in that, The biomaterial is any one of the following: A1) A nucleic acid molecule that encodes the heavy chain variable region and the light chain variable region of the monoclonal antibody or its antigen-binding fragment as described in claim 1 or 2; A2) An expression cassette containing the nucleic acid molecules described in A1); A3) A recombinant vector containing the nucleic acid molecules described in A1); A4) Recombinant microorganisms containing the nucleic acid molecules described in A1); A5) Recombinant host cells containing the nucleic acid molecules described in A1).

4. The biomaterial according to claim 3, characterized in that, The nucleic acid molecules are the DNA molecules shown in SEQ ID No. 2 and SEQ ID No.

4.

5. The use of the monoclonal antibody or its antigen-binding fragment as described in claim 1 or 2, or the biological material as described in claim 3 or 4, in any of the following: B1) Use in the preparation of products for inhibiting or neutralizing rotavirus activity; B2) Application in the preparation of products for detecting rotavirus or rotavirus VP8* protein; B3) Application in the preparation of products for binding to rotavirus or rotavirus VP8* protein; B4) Use in the preparation of products for the diagnosis or auxiliary diagnosis of rotavirus infection or diseases caused by rotavirus infection; B5) Use in the preparation of products for screening or assisting in the screening of rotavirus infection or diseases caused by rotavirus infection.

6. The application according to claim 5, characterized in that, The rotavirus is a group A rotavirus or a group A rotavirus with the following genotypes: P[1], P[6], P[7], P[8], P[13] and / or P[23].

7. An antibody conjugate, comprising an antibody portion and a conjugation portion, characterized in that, The antibody portion comprises the monoclonal antibody or its antigen-binding fragment as described in claim 1 or 2.

8. A reagent kit, characterized in that, The kit contains the monoclonal antibody or its antigen-binding fragment as described in claim 1 or 2, or the antibody conjugate as described in claim 7.

9. A method for detecting rotavirus or rotavirus VP8* protein for non-disease diagnostic and therapeutic purposes, characterized in that, The method includes detecting rotavirus or rotavirus VP8* protein using the monoclonal antibody or its antigen-binding fragment as described in claim 1 or 2, the antibody conjugate as described in claim 7, or the kit as described in claim 8.

10. A method for preparing the monoclonal antibody or its antigen-binding fragment according to claim 1 or 2, characterized in that, The preparation method includes expressing the monoclonal antibody or its antigen-binding fragment as described in claim 1 or 2 in a host cell, and recovering or separating the monoclonal antibody or its antigen-binding fragment.